Experimental data from both animal models and clinical trials have demonstrated that the reconstituting immune system plays an important role in the eradication of malignant cells after allogeneic bone marrow transplantation (BMT). [1] [2] [3] [4] This immunologic effect has been termed graftversus-leukemia (GVL). Although the precise mechanisms and target antigens of the GVL response have not yet been established, the most direct evidence for the importance of GVL comes from the demonstration that infusion of donor lymphocytes, without additional therapy, can induce remissions in patients with relapsed hematologic malignancies after allogeneic BMT. [5] [6] [7] [8] Although remissions after donor lymphocyte infusion (DLI) can be observed in patients who do not develop GVHD, the majority of responses are associated with significant GVHD. 6, 7, 9 Attempts to reduce the incidence and morbidity of GVHD post DLI have included both reduction of the total number of infused allogeneic lymphocytes and infusion of selected subsets of donor T cells. [10] [11] [12] Both of these approaches have been reported to be effective, suggesting that GVHD and GVL can be distinct immunologic effects mediated by different T cell populations.
Although multiple myeloma (MM) is not curable with conventional therapy, high-dose ablative therapy followed by either autologous or allogeneic stem cell support can result in long-term survival of some patients. [13] [14] [15] [16] [17] However, despite the effectiveness of myeloablative therapy, the incidence of multiple myeloma relapse after BMT is relatively high. 14, 16 Relapse rates appear to be lower in patients who have received allogeneic stem cells suggesting that a graftversus-myeloma (GVM) effect also develops in these patients. 18 Nevertheless, the increased toxicity associated with GVHD and immune suppressive therapy has been prohibitively high in some studies, negating the potential benefits of a GVM effect. 13, 18 Clinical remissions have also been reported in patients with relapsed myeloma who received DLI after allogeneic BMT providing more direct evidence for the development of a GVM effect. 6, [19] [20] [21] [22] Analysis of T cell receptor (TCR) V␤ repertoire has been shown to be a powerful method for the in vivo characteriz-ation of immune responses. Based on the PCR amplification of 24 distinct TCR V␤ subfamily genes, this technique characterizes the relative utilization of each V␤ gene subfamily and can also identify clonal and oligoclonal T cell populations within each subfamily. Serial analysis of patient samples can therefore identify changes in the relative utilization of each TCR V␤ gene subfamily as well as the relative expansion or regression of clonal T cell populations. Using this method, previous studies have demonstrated the presence of identical clonal and oligoclonal T cell populations in both GVHD lesions and peripheral blood. [23] [24] [25] Studies from our laboratory have also demonstrated that this method can be used to identify new clonal T cell populations in blood samples from patients with chronic myelogenous leukemia (CML) responding to DLI. 26 In these and other examples, analysis of TCR V␤ repertoire has been able to detect clonal T cell populations that were not evident using other immunologic methods. 27 In the present studies, we undertook a detailed analysis of TCR V␤ repertoire following donor lymphocyte infusion in four patients with relapsed multiple myeloma after allogeneic BMT. This analysis of CDR3 profiles demonstrated the emergence of clonal T cell populations after DLI in three patients with clinical responses. The appearance of some clones was noted early after DLI and coincided with decreasing levels of monoclonal paraprotein suggestive of an ongoing GVM response. Other T cell clones appeared at later time points and coincided with the development of GVHD. These results suggest that GVM and GVHD are mediated by distinct T cell populations, and further characterization of clones with different patterns of onset following DLI can be directed towards identification of the target antigens of these immune responses.
Materials and methods

CD4
+ donor lymphocyte infusions Serial blood samples were obtained from four patients with relapsed multiple myeloma (MM) who were enrolled in a clinical trial to evaluate the toxicity and immunologic effects of escalating doses of allogeneic CD4 + lymphocytes. 12 Donor T cells were obtained by leukopheresis from the same HLA-identical sibling that had previously donated marrow for allogeneic BMT. The isolation of mononuclear cells from the leukopheresis product and the method for depletion of CD8-positive cells have been previously described. 12 Patients described in this report received either 1 × 10 8 or 1.5 × 10 8 CD4 + cells/kg. Donor lymphocyte infusions contained Ͻ1% CD8 + cells. All therapy was discontinued prior to DLI and patients received no other immune modulating therapy after DLI. The clinical research protocol for this trial was approved by the Human Subjects Protection Committee of the Dana-Farber Cancer Institute and informed consent was obtained from each patient and donor.
RNA extraction, reverse transcription and polymerase chain reaction
Heparinized blood samples were obtained from patients receiving CD4
+ DLI as well from their normal HLA-identical sibling donors. Peripheral blood mononuclear cells were isolated by Ficoll/Hypaque density gradient centrifugation and cryopreserved. For TCR V␤ analysis samples from different time points were thawed and enriched for T lymphocytes by immunomagnetic selection of CD3 + cells using MACS beads (Miltenyi Biotech, Sunnyvale, CA, USA). RNA was extracted from T cell preparations using the RNAStat-60 kit (Tel-test, Friendswood, TX, USA) according to the manufacturer's protocol. First-strand cDNA was generated from 2 g of total RNA using random hexanucleotides (Pharmacia Biotech, Piscataway, NJ, USA) and reverse transcriptase (Superscript, Gaithersburg, MD, USA). Each V␤ segment was amplified with one of the 26 V␤ subfamily specific primers and a C␤ primer recognizing both C␤1 and C␤2 regions. PCR amplification of V␤5 and V␤13 each required the use of two primers to identify the entire V␤ subfamily. The sequence of primers used in these experiments were described by Choi et al 28 except for the C␤ and V␤3, V␤19, V␤21, V␤22, V␤23 and V␤24 primers which were described by Puisieux et al. 29 The C␤ primer was conjugated to fluorescent dye 6-FAM (Applied Biosystems, Foster City, CA, USA) for CDR3 size analysis. The amplification was performed over 30 cycles in a final volume of 100 l on a DNA thermal cycler (Perkin-Elmer, Norwalk, CT, USA). The PCR cycle profile was denaturation at 94°C for 1 min, annealing at 55°C for 1 min, extension at 72°C for 1 min, and a final polymerization step of 10 min at 72°C. Experiments in which template DNA was titrated and in which the number of cycles was varied were carried out in order to ensure that the PCR reactions were linear under the conditions used, as demonstrated by a dose-response relationship between initial amounts of cDNA and quantity of the final products.
Quantitation of TCR V␤ subfamily representation in peripheral blood T cells
Twenty-five l (1/4) of each PCR reaction was electrophoresed on a 2% agarose gel and blotted to nylon membranes (Boehringer Mannheim, Mannheim, Germany). The membrane was hybridized at 42°C overnight with a 32 P ␥-ATPlabeled C␤ internal probe (5Ј-GAGGACCTGAA-CAAGGTGTTCCCACCCGAG-3Ј) and washed twice at 4°C for 30 min in 6 × SSC and twice at 65°C for 20 min in TMAC. The membrane was exposed to a Phosphor screen and radioactive intensity of each specific band was quantified on a PhosphorImager using ImageQuant software (Molecular Dynamics, Sunnyvale, CA, USA). Representation of each V␤ subfamily was calculated as a percentage of the sum of all V␤ signals detected on the autoradiogram.
T cell receptor ␤ chain CDR3 fragment size analysis
The size distribution of each fluorescent PCR product was determined by electrophoresis on an automated 373 DNA sequencer (Applied Biosystems) using a 5.5% polyacrylamide gel and data analyzed by GeneScan software (Perkin Elmer). Since the position of the 5Ј and 3Ј primers are fixed, fragment size differences within each V␤ subfamily are due entirely to different CDR3 region lengths, reflecting 625 junctional diversity and N-random nucleotide insertions in the V-D-J region. Peaks corresponding to in-frame transcripts are detected at three nucleotide intervals. As described previously, a normal transcript size distribution, reflecting polyclonal cDNA, contains eight to 10 peaks for each V␤ subfamily with a Gaussian size distribution. 30, 31 The appearance of dominant peaks indicates the presence of excess cDNA of identical size, suggesting the presence of an oligoclonal or clonal T cell population.
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Statistical methods
The significance of differences in the frequency of V␤ gene expression between normal T cells and patient T cells was determined by calculation of Z scores. We assume that the frequency of V␤ gene expression follows a Gaussian distribution. Means and standard deviations were obtained for utilization of 26 V␤ gene segments in normal T cells from 10 normal individuals. V␤ gene segment usage in patient T cells 360  360  360  360  400  360  360  360   360  360  360  360  360  400  360  360  400   360  360  360  360  400  360  360  360   360  360  360  360  360  400  360  360  400   400  400  360 360  320  480  440  520  400   400  400  360 360  320  480  440  520 + T cells from patient 2 and patient 3 before (panels a and c) and 4 months post DLI (panels b and d). Each PCR reaction was performed using a V␤ subfamily-specific primer and a common fluorescent C␤ primer recognizing both C␤1 and C␤2 regions. PCR products were run through a sequencing gel and analyzed on an automated DNA sequencer using GeneScan software. Fluorescence intensity (y axis) is plotted against CDR3 size (x axis).
was normalized using these reference values, and the resulting standardized value compared to the distribution of a Gaussian distribution with mean of 0 and standard deviation of 1. We characterized V␤ gene usage that was more than 2.58 standard deviations from the normal mean as abnormal. Under the Gaussian assumption, 1% of all such normal standardized values would be classified as abnormal.
Results
Patient histories
The clinical characteristics of the four patients examined in this study are summarized in Table 1 . Each patient underwent allogeneic BMT for relapsed multiple myeloma and received marrow from an HLA-identical sibling donor. In each case donor marrow was depleted of CD6-positive T cells and patients received no other prophylactic immune suppressive therapy to prevent GVHD post BMT. Following relapse, each patient received a defined number of CD4
Patient 1 is a 40-year-old male with IgG lambda multiple myeloma who underwent allogeneic BMT in April 1994. He relapsed in October 1994 and received DLI 3 months after relapse. Serum monoclonal protein began to decrease 4 weeks after DLI. However, serum monoclonal protein remained detectable for a prolonged period and the patient did not achieve a complete remission until 2 years after DLI. Five months after DLI he developed grade 2 GVHD requiring treatment with prednisone and cyclosporine. Chronic skin GVHD remains ongoing 3 years post DLI. Patient 2 is a 42-year-old male with IgA kappa multiple myeloma who underwent allogeneic BMT in February 1990. He relapsed in July 1994 and received DLI 9 months later. Beginning 2 months after DLI, a progressive decline in serum monoclonal protein was noted, but a complete response was not achieved. Four months after DLI he developed extensive chronic GVHD of the skin and liver requiring treatment with prednisone and cyclosporine. The patient remained in a minimal disease state until 2 years after DLI, when progressive disease was again documented.
Patient 3 is a 46-year-old female with light chain myeloma who underwent allogeneic BMT in April 1994. Following relapse in January 1995 she received radiation therapy and high-dose cyclophosphamide but continued to have progressive disease. She received DLI 7 months after initial relapse. Disease regression became evident 2 months post DLI and a complete response was noted 6 months post DLI, but the patient relapsed 2 months later with a single lytic bone lesion. Eleven months post DLI skin GVHD proBone Marrow Transplantation gressed to extensive disease requiring treatment with prednisone and cyclosporine.
Patient 4 is a 56-year-old male with IgG lambda myeloma who underwent allogeneic BMT in July 1991. He developed slowly progressive disease after BMT and received DLI in February 1995. One month post DLI he developed a bone plasmacytoma that was treated with dexamethasone and radiation therapy. Serum paraprotein levels decreased after radiation therapy but he again developed progressive disease 6 months post DLI, and no response was noted after a second donor lymphocyte infusion.
Evolution of TCR repertoire following DLI
To identify changes in the T cell repertoire associated with the infusion of donor lymphocytes, we first analyzed circulating T cells obtained before DLI for the relative utilization of each of the 24 TCR V␤ subfamilies. Results obtained prior to DLI were compared to a similar analysis carried out with samples from each patient at varying time intervals for at least 1 year after DLI as well as to results in 10 normal donors. The results of this analysis of relative TCR V␤ utilization prior to DLI and at 4 months post DLI are summarized in Figure 1 . Before DLI, when compared to the relative utilization of TCR V␤ in normal individuals, only patient 3 was found to have a markedly skewed repertoire with eight of 26 subfamilies abnormally represented. In the remaining three patients, only one or two TCR V␤ subfamilies were found to be statistically different from the group of normal donors (Figure 1a) . Four months after DLI, the abnormal TCR V␤ representation in patient 3 had normalized and no significant changes in relative representation of different V␤ genes were observed in the remaining three patients (Figure 1b) . Although the relative utilization of individual TCR V␤ genes varied in each patient during the first 12 months following DLI, these changes were transient and no consistent abnormalities were evident in the four patients we examined.
After demonstrating that the utilization of all TCR V␤ genes was not markedly skewed, further studies were undertaken to characterize the repertoire of T cells expressing each of the TCR V␤ genes through a detailed analysis of CDR3 patterns within each of the 24 TCR V␤ gene subfamilies. As shown in Figure 2 , the analysis of CDR3 profiles prior to DLI showed many abnormalities, with a large number of monoclonal patterns. In addition, many of the V␤ families demonstrated oligoclonal CDR3 profiles. Since some degree of deviation from the classical bell shape curve can be observed in normal individuals, only CDR3 profiles demonstrating a single predominant peak without any additional polyclonal peaks were considered to be monoclonal. Examples of such monoclonal profiles are highlighted in Figure 2 . Using these strict criteria, 16% of the TCR V␤ subfamilies in our patients showed monoclonal CDR3 patterns prior to DLI. In comparison, Ͻ5% of the CDR3 profiles in 10 normal donors demonstrated predominant clonal T cell populations. The degree of abnormality in each patient was different, ranging from a relatively normal repertoire in patient 2 (4% monoclonal patterns) to a very altered repertoire in patient 3 (31% monoclonal patterns). The complete analysis of the 24 TCR V␤ subfamilies for these two patients are shown in Figure  2a and c and predominant clonal patterns are designated with boxed labels. Using the same criteria, 23% of the TCR V␤ subfamilies were monoclonal in patient 1 and 8% were monoclonal in patient 4 (data not shown). Of note, patients 1 and 3, who displayed the highest frequency of monoclonal patterns, were both examined at relatively short intervals after BMT (9 and 16 months post BMT respectively, compared to 62 and 43 months post BMT for patients 2 and 4).
Following DLI, significant changes in TCR V␤ CDR3 patterns were observed in patients 1, 2 and 3 but not in patient 4. Several monoclonal and oligoclonal peaks present prior to DLI showed progressive normalization in the first months after DLI. However, some abnormal profiles persisted for more than 1 year post DLI. Several new monoclonal TCR V␤ profiles appeared several months following lymphocyte infusion. The complete analysis of TCR V␤ CDR3 profiles for patients 2 and 3 at 4 months post DLI is shown in Figure 2b and d for comparison with the pre-DLI samples. In patient 2, the 4 months post-DLI profile shows persistence of the clonal V␤1 pattern as well as the emergence of a new V␤3 clone that was not detectable prior to DLI. In patient 3, the 4 months post-DLI profile shows either resolution or improvement of all of the clonal patterns that were detectable pre-DLI.
Identification of TCR V␤ CDR3 clonal expansion associated with GVL and GVHD activity
Following DLI, the analysis of TCR V␤ CDR3 profiles demonstrated the appearance of new clonal or oligoclonal CDR3 patterns in all patients except for patient 4. The appearance of clonal peaks was associated with different degrees of amplification of the corresponding TCR V␤ gene subfamily (ranging between two-and 14-fold), but in no case did the expanded V␤ subfamily represent more than 10% of peripheral T cells. In these patients with relapsed multiple myeloma receiving DLI, the level of monoclonal protein present in serum was monitored and used as a marker of disease progression and response. In each of the three patients who demonstrated a clinical response to DLI, this M component began to decrease in the first 3 months following DLI. In contrast, no patients developed clinical or laboratory evidence of GVHD less than 4 months post DLI. Thus early appearing clones that became evident Ͻ3 months post DLI appeared to be temporally associated with graft-versus-myeloma (GVM) activity. In contrast, clones that appeared relatively late (у4 months) post DLI appeared to be associated with GVHD. Overall, one new clonal expansion in patient 1, two in patient 2, and two in patient 3 appeared in the first 3 months post DLI, concurrently with the onset of the clinical response. At the onset of GVHD, two new clones became evident in both patients 1 and 2, respectively. In patient 3, the severe GVHD she experienced 10 months after DLI was associated with an extensive skewing of the TCR repertoire and the appearance of four new clonal CDR3 patterns. The serial identification of five early and four late appearing clones that were followed over a 1-2 year period of clinical observation are shown in Figures 3 and 4 , respectively. The time of onset of clinical response, GVHD or relapse for each patient is also indicated.
Discussion
Several recent reports have documented the clinical efficacy of donor lymphocyte infusion in patients with relapsed multiple myeloma after allogeneic BMT. In a review of 140 patients with relapsed hematologic malignancies after allogeneic BMT, two of four patients with multiple myeloma achieved complete remissions after DLI. 6 Lokhorst et al 22 reported significant clinical responses to DLI in eight of 13 patients with relapsed myeloma. In a phase 1 clinical trial conducted at the Dana-Farber Cancer Institute, five of six patients with myeloma demonstrated significant responses, with three of these patients achieving a complete response after infusion of CD4 + DLI. 12 Taken together with reports Months post DLI Figure 3 Evolution of clonal T cell populations appearing Ͻ3 months post lymphocyte infusion. CDR3 profiles for 24 V␤ subfamilies were examined at periodic intervals before and for as long as 2 years after donor lymphocyte infusions in each patient. Sequential analysis in patients 1, 2 and 3 showed the appearance of five new clonal CDR3 patterns in the first 3 months following DLI. Arrows indicate the times of clinical response or relapse and the onset of GVHD. These clonal expansions were not evident prior to DLI and persisted for as long as 2 years post DLI. Clonal V␤7 and V␤20 CDR3 patterns in patient 3 normalized following complete remission and subsequently reappeared at the time of relapse.
of individual cases, 19, 20 this clinical experience provides direct demonstration of the ability of donor lymphocytes to mediate an effective graft-versus-myeloma (GVM) response after allogeneic BMT. Although the number of patients treated remains limited, the clinical remissions that have been documented and the lack of effective alternative treatments make DLI an attractive therapeutic approach for patients with multiple myeloma who have undergone allogeneic BMT.
In contrast to the limited evidence for GVM, there has been extensive clinical evidence for GVL in patients with
Bone Marrow Transplantation CML undergoing allogeneic BMT. 6, 7 Interestingly, there appear to be several clinical differences between GVM and GVL. For example, the GVL effect in patients with CML appears to be a very strong immunologic response resulting in a relatively low risk of relapse after allogeneic BMT. In contrast, relapse rates remain relatively high after allogeneic BMT in patients with multiple myeloma, and in some reports the risk of relapse is similar to the risk observed after autologous BMT. 18 In patients with CML, the risk of relapse is markedly decreased in patients with acute or chronic GVHD. 32, 33 In contrast, the risk of relapse in patients with myeloma is not clearly associated with the development of GVHD in all studies. 18 In part, these differences may be due to the fact that allogeneic BMT in myeloma is utilized primarily for patients with advanced and relatively refractory disease. 13, 34 In patients with CML, the GVL response also appears to be most effective in patients transplanted in their first chronic phase and least effective for patients in blast crisis. Alternatively, GVM and GVL may be distinct immunologic effects, or myeloma tumor cells may be inherently more resistant to the GVM response. It is not possible to distinguish between these alternative hypotheses without first developing a better understanding of the immunologic mechanisms responsible for GVL and GVM.
To better characterize the GVM response, we undertook a detailed analysis of the TCR repertoire in four patients with relapsed multiple myeloma who received infusions of CD4 + donor T cells. This analysis provided a sensitive method for detecting changes in T cell repertoire after DLI that could not be appreciated by routine flow cytometric analysis of peripheral T cells. Two patients presented only one or two clonal CDR3 patterns prior to DLI but two patients demonstrated clonal predominance in 23-31% of the V␤ subfamilies. Following DLI, most clonal patterns that were present prior to DLI resolved and were replaced by normal polyclonal patterns within 3-4 months after infusion. Of note, this finding appears to be different from results previously obtained in patients with relapsed CML responding to DLI. 26 Patients with relapsed CML had a large number of abnormal CDR3 patterns prior to DLI and these persisted for at least 3 months after DLI. Thereafter, clonal T cell populations in CML patients were only gradually replaced by polyclonal patterns over the next 9-12 month period of observation. In contrast to patients with CML, the relatively rapid resolution of clonal CDR3 patterns suggests that these abnormalities were not a direct result of the presence of myeloma cells which persisted for prolonged periods, even in patients who responded to DLI.
The principal aim of this study was the identification of clonal T cell populations that could be mediators of either anti-myeloma or anti-host effects following DLI. In fact, we were able to detect the appearance of new clonal CDR3 patterns in three of four patients analyzed. In these three patients, analysis of serial blood samples demonstrated the appearance of two groups of new clonal T cells that could be distinguished primarily by the time of onset after DLI. The first group of clonal T cells became evident approximately 1-3 months after DLI whereas the second group of new clones did not appear until more than 4 months after DLI. Interestingly, these time differences coincided with both the initial onset of tumor response and the subsequent onset of clinical GVHD in each of these patients. These differences therefore suggested that the early appearing clones may be candidate GVM clones whereas the late appearing clones may be potential mediators of GVHD.
Although we do not yet know the functional specificity of these particular clones, these results suggest that the infusion of donor lymphocytes can result in the expansion of T cell populations and that these clonal populations can subsequently persist for prolonged periods in vivo. The presence of idiotype-specific CD4
+ T cells has previously been documented in patients with myeloma after allogeneic BMT, 35 but the ability of these cells to eliminate myeloma cells in vivo may be limited and the effectiveness of these cells may be enhanced by providing additional donor CD4 + T cells. The finding that putative GVM clones identified in our patients became evident several months before GVHD developed suggests that they may be specific for idiotype or other tumor-associated antigens selectively expressed on myeloma cells, 36 and not widely expressed on nonhematopoietic recipient cells.
In contrast to GVM, no patients developed any evidence of GVH in the first 4 months after DLI. This led to the identification of putative GVH clones that did not become apparent within the CDR3 profiles until 4-6 months after DLI. These clones are therefore likely to represent a newly developing response that was not present prior to DLI. In recent studies, T cell clones specific for minor histocompatibility antigens have been identified as potential mediators of GVHD. 37 Although the specificity of putative GVH clones in our patients has not been determined, the delayed appearance of these cells suggests that these clones are not likely to be responsible for the anti-myeloma effect observed in these patients.
Having developed molecular methods to selectively identify different T cell populations, further efforts can now be directed to isolate and expand these specific T cells in vitro. Functional analysis of these expanded T cell clones will be necessary to determine the specificity of these cells and to examine their potential role in either anti-myeloma or anti-host reactions following DLI. Although clinical remissions can now be obtained with DLI in increasing numbers of patients, the immunological mechanisms involved are still largely unknown. The durability of these responses, especially in patients with myeloma, also continues to be an unresolved problem. The molecular analysis of TCR repertoire, employed in this study to identify changes in the T cell compartment induced by DLI, may provide new insights into the immune mechanisms responsible for these clinical effects in vivo. This may be helpful in improving the durability of response in patients with myeloma and extending this immunotherapeutic approach to other patient populations that do not currently respond to DLI.
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